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ABSTRACT 
Background: Mechanism of action of nevirapine in the prophylaxis treatment and treatment of HIV-1 may involve 
elevations in levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase and other biomarkers of 
liver function. This study presents the hepatotoxic effect of nevirapine suspension using animal model. 
Methods: A total number of 15 male Wister rats were fed normal chow and antiretroviral drug (Nevirapine) for a period of 
six weeks. The liver organ of the rats were obtained and subjected to histological procedures and biochemical analysis 
using enzyme assay obtained from Randox Laboratories Limited, Antrim United Kingdom (BT294QY). 
Results: The wistar rats showed no significant mean body weight difference when compared with the control group. 
However there was significant difference in the mean values of AST (77.77±3.03) and ALT (89.37±3.19) of the treated rats. 
Nevirapine treated rats showed significant difference in AST, ALT, and ALP in the single (77.77± 3.03, 31.80±1.73, 43.81 
±1.54) and double (89.37±3.19, 33.38±2.01, 34.64 ±1.02) doses when compared with the controls (75.14 ±2.00, 29.16±0.17, 45.44 
±1.85) respectively.  Mild vascular congestion, infiltration of sinusoids by inflammatory cells, and haemorrhage were 
induced by nevirapine as compared with the control group showing normal vessels without congestion, normal sinusoids 
appearing normal without infiltration. 
Conclusion: The liver histology of the rats fed with Nevirapine suspension showed diffused hepatocellular necrosis. 
Routine check of the drug effect is important as it provides effective life management of HIV infected individuals.   
Keywords: Nevirapine, Wister rat, Hepatotoxicity, Liver, Alanine aminotransferase (ALT), Aspartate aminotransferase 
(AST), Alkaline phosphatase (ALP). 
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RÉSUMÉ  
Contexte: Mécanisme d'action de la névirapine dans le traitement de prophylaxie et le traitement du VIH-1 peut impliquer 
élévations des taux d'alanine aminotransférase, aspartate aminotransférase, la phosphatase alcaline et d'autres 
biomarqueurs de la fonction hépatique. Cette étude présente l'effet hépatotoxiques de la suspension de la névirapine en 
utilisant un modèle animal. 
Méthodes: Un nombre total de 15 rats mâles Wistar ont été nourris chow normal et médicament antirétroviral (névirapine) 
pour une période de six semaines. L'organe du foie des rats ont été obtenus et soumis à des procédures histologiques et 
analyse biochimique utilisant un dosage de l'enzyme obtenue à partir de Randox Laboratories Limited, Antrim Royaume-
Uni (BT294QY). 
Résultats: Les rats Wistar ont montré aucune différence significative de poids corporel moyen en comparaison avec le 
groupe témoin. Cependant il y avait de différence significative dans les valeurs moyennes d'AST (77,77 ± 3,03) et ALT (89,37 
± 3,19) des rats traités. Névirapine chez les rats traités ont montré de différence significative dans AST, ALT et ALP dans la 
seule (77.77 ± 3.03, 31.80 ± 1.73, 43.81 ± 1.54) et double (89.37 ± 3.19, 33.38 ± 2.01, 34.64 ± 1.02), des doses en comparaison avec 




par des cellules inflammatoires, et des hémorragies ont été induites par la névirapine par rapport au groupe de contrôle 
montrant les vaisseaux normaux sans congestion, sinusoïdes normales apparaissant normale sans infiltration. 
Conclusion: L'histologie hépatique des rats nourris avec névirapine suspension a montré une nécrose hépatocellulaire 
diffuse. Contrôle de routine de l'effet du médicament est importante car elle permet une gestion efficace de la vie des 
personnes infectées par le VIH. 
 
Mots-clés: Névirapine, Wister rat, Hépatotoxicité, Foie, de l'alanine aminotransférase (ALT), d'aspartate aminotransférase 
(AST), la phosphatase alcaline (ALP). 
INTRODUCTION 
Nevirapine (NVP) is a non-nucleoside reverse 
transcriptase inhibitor (NNRTI) used for 
prophylaxis and treatment of Human 
Immunodeficiency Virus (HIV) infections [1,2]. It 
acts by reversibly inhibiting the activity of HIV-1 
reverse transcriptase, an enzyme which directs the 
polymerization of DNA from viral RNA, a 
necessary component for HIV-1 replication [3]. The 
inhibition of reverse transcriptase-directed 
polymerization of DNA from viral RNA has been 
an important therapeutic target for the treatment of 
HIV-1 infection, which was initially reported with 
the nucleoside analogue AZT [4]. Unlike the 
nucleoside analogues, NVP binds directly to the 
reverse transcriptase at amino acid residues 181 and 
188. This site is close to but not directly at the 
polymerase catalytic site on the large subunit of the 
heterodimeric reverse transcriptase. The binding of 
NVP to reverse transcriptase occurs primarily 
through hydrophobic interactions to a pocket 
formed by seven strands, as a result the rate of the 
chemical reaction catalysed by the reverse 
transcriptase is significantly slowed [5]. NVP does 
not exhibit activity against other viral polymerase, 
including HIV-2 and simian immunodeficiency 
virus reverse transcriptase. NVP has been studied 
in several combination regimens for the treatment 
of HIV [6]. 
As nevirapine dose administered to mother and 
infant has been widely used to prevent mother-to-
child transmission of HIV-1 in resource-limited 
settings [7], it has also been associated with severe 
skin and hepatic hypersensitivity reactions that 
have hampered its use particularly for HIV 
prophylaxis [8]. Hepatotoxic effect of NVP is 
common in patients with higher CD4 counts and 
also in the first three weeks of NVP treatments in 
HIV infected subjects [9,10]. The immune pathways 
that consequently cause the liver damage have been 
likened to the pathogenesis of liver injury in 
diseases such as hepatitis B virus (HBV) and 
hepatitis C virus (HCV) infections where activated 
cell-mediated immunity is incriminated for the liver 
damaged [11,12]. The fact that NVP-induced 
hepatotoxicity is common in patients with higher 
CD4 counts imply that increased stimulation of the 
cell-mediated immune system response in some 
HIV-positive patients may predispose them to 
NVP-induced hepatotoxicity. According to Stern et 
al., [13] and Dieterich et al., [14], the mechanism of 
NVP-induced hepatotoxicity remains unknown, 
however, it was postulated to be immune mediated. 
Such immune mediation has already been proven in 
animal models for NVP-induced skin reactions 
[15,16]. Hepatotoxicity, a case of liver dysfunction 
or liver damage, is sometimes associated with an 
overload of drugs or xenobiotics, producing a wide 
variety of clinical and histopathological indicators 
of hepatic injury, however, the measurement of 
some level of substances that may be present in the 
blood helps in initial detection [17,18,19].  
Several enzymes that trigger important chemical 
reactions in the body are produced and found 
within the cells of the liver, however, damage or 
injury to the liver cause elevations to the liver 
enzyme levels. These enzymes include alanine 
aminotransferase (ALT), aspartate aminotransferase 
(AST), alkaline phosphatase (ALP) and bilirubin. 
Elevations in serum enzyme levels are taken as the 
relevant indicators of liver toxicity whereas 
increases in both total and conjugated bilirubin 
levels are measures of overall liver function [20]. 
Other measurable liver function is reflected in 
albumin and total protein concentration and the 
prothrombin time, which are the markers of liver 
biosynthetic capacity [3,5]. 
As HAART can substantially extend an HIV 
patient’s life, one of the major problems are its 
adverse systemic and oral effects. To examine the 
mechanism of effect of nevirapine, an examination 
of the histological and biochemical markers of liver 
using wistar rats administered nevirapine were 
compared to those who were not given for a period 
of six weeks. 
 
 
MATERIALS AND METHODS 
Animals  
 Fifteen male adult wistar rats were obtained from a 
breeding stock maintained in the animal house of 
the Agricultural Science Department, Ladoke 
Akintola University of Technology (LAUTECH), 
Ogbomoso, and housed in well ventilated plastic 
cages in animal house in Department of Pure and 
Applied Biology, LAUTECH, Ogbomoso. The rats 
were maintained under standard natural 
photoperiodic condition of twelve hours of light 
alternating with twelve hours of darkness (i.e. 
L:D;12h:12h photoperiod) at room temperature, 
allowed unrestricted access to water and rat chow 




commencement of the experiment. The body 
weights of the rats ranged between 180 and 300g. 
Drugs and Source 
The antiretroviral drug (Nevirapine) used was 
produced for Evans Medical Plc Nigeria by CIPLA 
Limited, Verna Indl. Estate Goa 403 722 India with 
Batch No.G10930 and National Agency for Food 
Drug Administration and Control (NAFDAC) reg. 
No. 04-9498.  
Experimental procedure  
Fifteen male wistar rats were randomly distributed 
into three groups with five rats per group. 
Corresponding therapeutic doses for rat models 
were calculated and aqueous solutions formed were 
administered daily as follows. Rats in groups 1 
(Control) received 0.9% food and normal saline. 
Group 2 (single dose) received 0.01% of Nevirapine, 
food and normal saline. Group 3 (double dose) 
received double dose of Nevirapine, food and 
normal saline. 
Animal sacrifice and sample extraction 
Animals were weighed and sacrificed after six 
weeks treatment. Blood samples were obtained by 
cervical dislocation and collected into EDTA bottles. 
Serum was used for the hepatic enzymes activities 
(ALT, AST and ALP).  
Histological Procedures and Analysis of the liver 
The liver organs were cut on slabs (0.5cm thick) and 
fixed in 10% formol saline for a day after which 
they were transferred to 70% alcohol for 
dehydration. The tissues were passed through 90% 
alcohol and chloroform for different durations 
before transferred into two changes of molten 
paraffin wax for 20min each in an oven at 57ºC. 
Serial sections of 5µm thick were obtained from a 
solid block of tissue and stained with haematoxylin 
and eosin stains, after which they were passed 
through a mixture of equal concentration of xylene 
and alcohol. Following clearance in xylene, the 
tissues were oven- dried. Photomicrographs were 
taken with a JVC colour video digital camera (JVC, 
China) mounted on an Olympus light microscope 
(Olympus UK Ltd, Essex, UK) to demonstrate the 
cytoarchitecture of the liver. 
Biochemical Analysis 
The analysis of the result for ALT, AST and ALP 
were done using SPSS program for windows (17.0 
version). The reagents used for the enzyme assay 
were obtained from the Randox Laboratories 
Limited, Antrim United Kingdom (BT294QY). 
RESULT                                                                                                                             
The mean body weight gain of the rats treated with 
antiretroviral drug as shown in Table 1 has no 
significant differences when compared with the 
control group that received distilled water and food 
for 6 weeks.  
Table 2 shows significant differences in ALP, AST 
and ALT. AST and ALT mean values increased as 
compared to the control, however, ALP mean value 
decreased when compared with the control. 
 
TABLE 1:    MEAN BODY WEIGHT OF RAT 
Group/Day 1-7 8-14 15-21 22-28 29-35 36-42 
1 158.09 ± 0.39 166.07 ± 0.43 154.04 ± 0.34 124 ± 0.17 144.04 ± 0.25 157.06 ± 0.34 
2 159.06 ± 0.41 142 ± 0.21 156 ± 0.38 164.05 ± 0.42 138 ± 0.28 140.02 ± 0.20 
3 160 ± 0.38 145 ± 0.30 155.04 ± 0.35 200.6 ±0.46 240.03 ± 0.51 234 ± 0.48 
Key:  Group 1- Control              Group 2 - Single dose                  Group 3-Double dose 
TABLE 2: EFFECTS OF NEVIRAPINE ON LIVER FUNCTIONS 
Biochemical Markers Group1 Group2 Group3 
AST (U/L) 75.14 ±2.00 77.77± 3.03 89.37±3.19 
ALT (U/L) 29.16±0.17 31.80±1.73 33.38±2.01 
ALP (U/L) 45.44 ±1.85 43.81 ±1.54 34.64 ±1.02 




Plates 1, 2 and 3 show the gross morphology of liver 
for rats fed with NVP as compared with the control.  
Those fed with NVP suspension showed diffused  
hepatocellular necrosis in about 90% of the rats. No 
such changes were observed in the control. 
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PLATE 1: MICROGRAPH OF LIVER SECTION OF RATS IN THE CONTROL GROUP 
Normal vessles without congestion (white arrow), 
the sinusoids (slender arrow) appear normal 
without  infiltration, the hepatocytes  show normal 
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PLATE 2(CTD.): MICROGRAPH OF LIVER SECTION OF RATS FED WITH SINGLE DOSE OF NEVIRAPINE SUSPENSION 
The central vessel appear normal (white arrow), 
there is mild congestion of the portal vein (black 
arrow) and focal area of mild haemorrhage (red 
arrow), the sinusoids shows mild infiltration of 
inflammatory cells (slender arrow)  the hepatocytes  
show normal morphology (blue arrow). 
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PLATE 3: MICROGRAPH OF LIVER SECTION OF RATS FED WITH DOUBLE DOSE OF NEVIRAPINE 
SUSPENSION 
There is mild vascular congestion (black arrow), the 
sinusoids show mild infiltration by inflammatory 
cells, there is focal granuloma within the liver 
parenchyma (white arrow), the hepatocytes show 
normal morphology (blue arrow). 
 
DISCUSSION 
Effects of administration of NVP given orally on 
morphology of the liver of albino wistar rats were 
studied. Nevirapine is one of the most widely used 
antiretroviral drugs in the treatment of human 
immunodeficiency virus infections. Its mechanism 
of action is not limited to treatment of HIV-1 but 
also in the reduction of mother-to-child 
transmission of HIV-1 which may involve reduction 
of maternal viral load as well as prophylaxis of 
infants [2]. The drug can be used as a single-dose or 
as a combination therapy with other antiretroviral 
drugs including lamivudine, stavudine and 
Zidovudine [21,22,23,24]. Nevirapine 
administration has been associated with severe skin 




hampered its use particularly for HIV prophylaxis 
[25,26,8] as well as oral adverse effects, including 
whitish plaque in the lips and bilateral buccal 
mucosa, burning, taste disturbance, and xerostomia 
[1].   
From this study, no significant difference was 
recorded in the mean body weight of the rats fed 
with NVP as compared with those in the control 
group. This supports the findings from a similar 
study by Ayeni et al., [24].  
As revealed from the result in this study, 
Nevirapine is associated with significant activities 
of ALT and AST. Elevated activities of these 
enzymes indicate hepatic damage which results 
from several mechanisms including generation of 
toxic species and peroxidation of membranes [21]. 
The results showed that AST mean values were 
significantly increased in rats treated when 
compared with the control values. This elevation in 
Nevirapine treated rats agrees with earlier reports 
of Sule et al., [23], Johnson and Baraboutis [27] and 
Martinez et al., [9]. However, Nevirapine treated 
rats showed significant reduction in the values of 
ALP when compared with the control. According to 
Dufour et al., [28,29], ALT activity is the most 
frequently relied biomarker of hepatotoxicity in that 
it plays a vital role in amino acid metabolism and 
gluconeogenesis. The estimation of this enzyme is 
more specific for liver abnormalities since it is 
primarily located in the liver [30]. Aspartate 
aminotransferases (AST) is another liver enzyme 
found in the liver and other organs including heart, 
muscle, brain and kidney. Injury to any of these 
tissues can cause an elevated blood level [30]. It 
helps in detecting hepatocellular necrosis but is 
considered a less specific biomarker enzyme for 
hepatocellular injury [31]. It can also signify 
abnormalities in heart, muscle, brain or kidney 
[28,29]. According to Nathwani et al., [30], the ratio 
of serum AST to ALT can be used to differentiate 
liver damage from other organ damage. Alkaline 
phosphatase (ALP) may be elevated if bile excretion 
is inhibited by liver damage. Increase in alkaline 
phosphatase and/or bilirubin with little or no 
increase in ALT is primarily a biomarker of 
hepatobiliary effects and cholestasis [32]. In 
humans, increased ALP levels have been associated 
with drug-induced cholestasis [33].  As revealed 
from the result in this study, nevirapine is 
associated with significant elevated activities of 
ALT and AST. The result shows that AST mean 
values were significantly increased in rats treated 
with the antiretroviral drug when compared with 
the control values, which agrees with earlier reports 
of Umar et al. [21], Sule et al., [23], Johnson and 
Baraboutis [27] and Martinez et al. [9]. They 
concluded that nevirapine could be associated with 
hepatotoxicity. Nevirapine hepatotoxicity could be 
associated with some risk factors including gender, 
CD4 cell count, co-infection with hepatitis B or C 
and pregnancy [34,35,36,37,2,38]. Several drugs 
known to induce hepatotoxicity, like nevirapine, in 
association with an activated immune system 
include diclofenac [39], paracetamol [40], bacterial 
lipopolysaccharide (LPS) plus ranitidine [41] and 
trovafloxacin [42]. The elevation of enzymes 
activity, especially in ALT in Nevirapine-treated 
rats is indicative of liver injury. This agrees with 
reports that severe hepatic reactions of HAART was 
attributed to Nevirapine component of HAART 
[27,9]. Sulkwosk et al., [43] also reported 
hepatotoxicity as a major side effect of all 
antiretroviral classes with Nevirapine having the 
highest risk. Liver converts drugs into reactive 
forms and hence results in toxicity [21].  
Histological examination of NVP administration on 
the morphology of some organs of the body have 
been reported and series of reports as regards the 
toxicity of NVP a non-nucleoside reverse 
transcriptase inhibitor on the small intestine, 
kidney, spleen, mitochondria, bile, muscle and bone 
had been recorded [44,45,46,47,24]. The gross 
morphology of the liver from rats fed NVP 
observed in this study agrees with that reported by 
Umoren and Osim [3]. From result of this study as 
shown in Plate 1 revealed a normal healthy state of 
the liver with the portal tract intact. There are 
normal vessels without congestion, periportal 
hepatocytes arranged in plates and sinusoids 
appeared normal without infiltration, within the 
portal tract were the portal vein, hepatic artery and 
bile duct, no pathological lesion is seen. From plate 
2, the liver of the rats showed disorganized cyto-
architecture with sinusoidal and central vein 
endothelial desquamation. It revealed mild 
congestion of the portal vein and focal area of mild 
haemorrhage, the sinusoids showed mild 
infiltration of inflammatory cells, mild  perivascular  
infiltration, the sinusoids are mildly infiltrated by 
inflammatory cells even though the hepatocytes  
showed normal morphology. Plate 3 revealed poor 
architecture of the liver. There was mild vascular 
congestion with the sinusoids showing mild 
infiltration by inflammatory cells. A focal area of  
granuloma within the liver parenchyma was seen. 
There was mild congestion of the portal vein which 
shows that much damages was done in the liver of 
the rat administered with double dose of 
Nevirapine. The present result agrees with studies 
of Degott [48] who reported that liver damage is 
associated with alteration in bile secretion and 
Akerlund et al., [49] who showed that there is 
always an increase in cholesterol synthesis when 
there is a disturbance in bile release and utilization 
due to liver damage.  
Umoren and Osim [3] earlier reported the effects of 
NVP administration given through oral gavage on 




albino wistar rats. The result obtained showed 
significantly decreased biliary secretions resulting 
in insignificant increase in conjugated bilirubin but 
significant elevations in total cholesterol, total 
bilirubin, and unconjugated bilirubin. Also, 
significant decreases in biliary electrolytes 
concentrations were observed. 
Furthermore, Poirier et al., [50] and Ayeni et al., [24] 
reported that NVP can cause acute kidney injury as 
a result of severe mitochondrial dysfunction and 
lactic acidosis induced as well as acute renal failure 
after the initiation of NVP during the study of the 
effects of NVP on foetal parameters, kidney and 
spleen of dams. 
Conclusion 
The above results suggest that NVP administration 
may cause liver hepatotoxicity in albino wistar rats. 
The effect of antiretroviral drugs on biochemical 
indices of liver function is of paramount importance 
and should not be overlooked. This is to ensure that 
the liver function is not impaired in the process of 
managing a particular health problem in case of 
HIV patient, hoping to minimize the duplication of 
this virus in the human system, while a lot of harm 
is being done to the liver. The observation that it 
takes some weeks to develop liver injury means 
that NVP itself plays a role in the initiation of the 
lesion. Therefore, it can be concluded that NVP 
activates the cell-mediated immune response 
leading to liver injury that is propagated by the 
drug itself or the immune system. 
Following the results in this study and various 
reports on related studies, it could be concluded 
that the lives of HIV patients on regular use of 
HAART containing Nevirapine are prone to risk. 
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